YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome. / Kornblit, Brian; Wang, T; Lee, S J; Spellman, S R; Zhu, X; Fleischhauer, K; Müller, Catharina; Verneris, M R; Müller, Klaus; Johansen, Julia Sidenius; Vindeløv, Lars; Garred, Peter.
In: Bone, Vol. 51, No. 12, 2016, p. 1556-1560.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome
AU - Kornblit, Brian
AU - Wang, T
AU - Lee, S J
AU - Spellman, S R
AU - Zhu, X
AU - Fleischhauer, K
AU - Müller, Catharina
AU - Verneris, M R
AU - Müller, Klaus
AU - Johansen, Julia Sidenius
AU - Vindeløv, Lars
AU - Garred, Peter
PY - 2016
Y1 - 2016
N2 - YKL-40, also called chitinase-3-like-1 protein, is an inflammatory biomarker that has been associated with disease severity in inflammatory and malignant diseases, including AML, multiple myeloma and lymphomas. The objective of the current study was to assess the prognostic value of pretransplant recipient and donor plasma YKL-40 concentrations in patients with AML (n=624) or myelodysplastic syndrome (n=157) treated with allogeneic hematopoietic cell transplantation (HCT). In recipients, the plasma YKL-40 concentrations were increased when the HCT-comorbidity index was ⩾5 (P=0.028). There were no significant associations between plasma YKL-40 concentrations in recipients and any outcome measures. In donors with YKL-40 plasma concentrations above the age-adjusted 95th percentile, a trend toward increased grade II-IV acute GvHD in recipients was observed (adjusted hazard ratio 1.39 (95% confidence interval 1.00-1.94), P=0.050), with no significant associations with overall survival, treatment-related mortality or relapse. In conclusion, our study shows that YKL-40 does not aid risk stratification of patients undergoing allogeneic HCT, but suggests that YKL-40 may aid donor selection when multiple, otherwise equal, donors are available.
AB - YKL-40, also called chitinase-3-like-1 protein, is an inflammatory biomarker that has been associated with disease severity in inflammatory and malignant diseases, including AML, multiple myeloma and lymphomas. The objective of the current study was to assess the prognostic value of pretransplant recipient and donor plasma YKL-40 concentrations in patients with AML (n=624) or myelodysplastic syndrome (n=157) treated with allogeneic hematopoietic cell transplantation (HCT). In recipients, the plasma YKL-40 concentrations were increased when the HCT-comorbidity index was ⩾5 (P=0.028). There were no significant associations between plasma YKL-40 concentrations in recipients and any outcome measures. In donors with YKL-40 plasma concentrations above the age-adjusted 95th percentile, a trend toward increased grade II-IV acute GvHD in recipients was observed (adjusted hazard ratio 1.39 (95% confidence interval 1.00-1.94), P=0.050), with no significant associations with overall survival, treatment-related mortality or relapse. In conclusion, our study shows that YKL-40 does not aid risk stratification of patients undergoing allogeneic HCT, but suggests that YKL-40 may aid donor selection when multiple, otherwise equal, donors are available.
KW - Journal Article
U2 - 10.1038/bmt.2016.192
DO - 10.1038/bmt.2016.192
M3 - Journal article
C2 - 27427920
VL - 51
SP - 1556
EP - 1560
JO - Bone
JF - Bone
SN - 8756-3282
IS - 12
ER -
ID: 174235746